EQT AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 342.9 SEK | -0.09% |
|
+5.87% | +20.28% |
| 11:17am | Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron | DJ |
| 11:14am | EQT Unit Invests in Biotechnology Company Asceneuron | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
EQT AB is a Sweden-based differentiated global investment company. It manages and advises a range of specialized investment funds and other investment vehicles that invest across the world. The Company has three business segments: Private Capital, Real Assets and Credit. The Private Capital business segment invests in medium-sized to large companies in Europe and the United States, China and Southeast Asia, technology-driven companies across all industries and public companies. The Real Assets business segment invests in infrastructure and real estate businesses. The Credit segments offers an investment platform.
Calendar
2024-07-17
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
29.71
EUR
Average target price
31.61
EUR
Spread / Average Target
+6.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.28% | 38.38B | |
| +1.73% | 36.11B | |
| 0.00% | 20.42B | |
| +5.35% | 5.44B | |
| +4.24% | 4.15B | |
| +3.23% | 3.3B | |
| +26.18% | 3.03B | |
| -10.10% | 2.62B | |
| +3.52% | 1.23B | |
| +5.71% | 1.2B |
- Stock Market
- Equities
- EQT Stock
- News EQT AB
- EQT Unit Invests in Biotechnology Company Asceneuron
